Abel de la Rosa
Nessuna posizione attualmente
Patrimonio netto: 860 $ in data 31/05/2024
Profilo
Abel de la Rosa worked as a Director at Celtaxsys, Inc. He was also a Vice President-Product Development at Visible Genetics, Inc. from 2002 to 2002.
Additionally, he held the position of Senior VP-Business Development & Scientific Affair at Pharmasset, Inc. from 2011 to 2012.
Dr. de la Rosa completed his undergraduate degree at the University of California San Diego.
He also completed his graduate and doctorate degrees at the University of Miami.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 25/04/2024 | 4 000 ( 0.01% ) | 860 $ | 31/05/2024 |
Precedenti posizioni note di Abel de la Rosa
| Società | Posizione | Fine |
|---|---|---|
Visible Genetics, Inc.
 Visible Genetics, Inc. Medical SpecialtiesHealth Technology Visible Genetics, Inc. manufactures and markets automated DNA sequencing systems and diagnostic kits. The company develops genotyping technology that employs DNA sequencing that enables the analysis in the clinical diagnostic laboratory of individual genetic variations. It was founded in 1993 and is headquartered in Toronto, Canada | Corporate Officer/Principal | 01/12/2002 |
Celtaxsys, Inc.
 Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | Direttore/Membro del Consiglio | - |
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Direttore Tecnico/Scientifico/R&S | 02/10/2012 |
Formazione di Abel de la Rosa
| University of California San Diego | Undergraduate Degree |
| University of Miami | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
Pharmasset, Inc.
Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Health Technology |
Visible Genetics, Inc.
Visible Genetics, Inc. Medical SpecialtiesHealth Technology Visible Genetics, Inc. manufactures and markets automated DNA sequencing systems and diagnostic kits. The company develops genotyping technology that employs DNA sequencing that enables the analysis in the clinical diagnostic laboratory of individual genetic variations. It was founded in 1993 and is headquartered in Toronto, Canada | Health Technology |
Celtaxsys, Inc.
Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | Health Technology |
- Borsa valori
- Insiders
- Abel de la Rosa
